Vetter is accelerating the expansion of its global clinical manufacturing network as demand for in-human trial materials continues to rise, the company has announced.
The global Contract Development and Manufacturing Organization (CDMO) is scaling its Vetter Development Service to add capacity, advanced technologies, and specialized expertise for early-stage biopharmaceutical production. The goal is to better support drug developers as programs move from laboratory research into clinical trials.
“Our continued global expansion reflects our holistic approach to supporting our customers with their clinical development,” says Dr. Claus Feussner, Senior Vice President of Vetter Development Service.
“By investing in both technology and capacity, we are working to provide our partners with the tailored early-stage manufacturing services they need for their molecules to progress from the lab to the clinic.”
US operations expand on strong demand
Vetter’s US clinical footprint continues to be a key growth engine. Its Skokie, Illinois facility has already supported more than 140 customers and over 350 compounds, with a significant share being early-stage biotech firms and start-ups.
The company is also pushing ahead with a major new build: a 160,000-square-foot clinical manufacturing facility in Des Plaines, Illinois. Construction is progressing on schedule, with steel structure completion nearing and interior work set to begin soon. Once operational in 2029, the site will significantly expand Vetter’s U.S. clinical manufacturing capacity.
In Europe, Vetter’s Rankweil, Austria facility is undergoing targeted upgrades to handle growing project volume and increasing complexity in drug product development.
Enhancements include a new weighing room, an additional aseptic compounding area, expanded manual visual inspection capacity, new cold-storage infrastructure, specialized freezer systems for API storage, and an added incubator chamber to strengthen microbiological testing.
With simultaneous expansion in Europe and the United States, Vetter is tightening integration across its clinical operations to ensure consistent quality standards, harmonized processes, and greater flexibility for global biotech clients.
The company says the strategy reinforces its position as a long-term partner for cGMP-compliant clinical development and sterile drug product filling services as competition for clinical manufacturing capacity intensifies.
_256_275.jpg)
